Expert Review of Pharmacoeconomics & Outcomes Research最新文献_第10页

Comparative efficacy of later-line therapies for metastatic colorectal cancer: a network meta-analysis of survival curves. 转移性结直肠癌后线疗法的疗效比较：生存曲线网络荟萃分析。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-10-01 Epub Date: 2024-06-18 DOI: 10.1080/14737167.2024.2365993

Mavis Obeng-Kusi, Jennifer R Martin, Denise Roe, Brian L Erstad, Ivo Abraham

{"title":"Comparative efficacy of later-line therapies for metastatic colorectal cancer: a network meta-analysis of survival curves.","authors":"Mavis Obeng-Kusi, Jennifer R Martin, Denise Roe, Brian L Erstad, Ivo Abraham","doi":"10.1080/14737167.2024.2365993","DOIUrl":"10.1080/14737167.2024.2365993","url":null,"abstract":"Introduction: We evaluated the comparative efficacy of six later-line (≥3) therapies for metastatic colorectal cancer (mCRC) over placebo. We applied a novel statistical method of reconstructing pseudo-patient-level data (pseudo-IPD) to inform a network meta-analysis of survival curves that considers shape in addition to scale parameters.Methods: A literature search yielded 10 phase II/III trials. We digitized all survival curves and applied a novel method incorporating curve coordinates, patients-at-risk, and events reported to generate pseudo-IPD. Using fitted random effects lognormal distributions, we estimated the survival proportions and HRs (95CrI) of progression-free (PFS) and overall survival (OS) over 12 months of follow-up.Results: Compared to placebo, in ascending order, 12-month OS HRs were 0.50 (95% CrI = 0.35, 0.69; PFS = 0.11 (95% CrI = 0.06, 0.14)) for TAS+bevacizumab; 0.71 (95% CrI = 0.51, 0.97; PFS = 0.26 (95% CrI = 0.16, 0.41)) for regorafenib; 0.75 (95% CrI = 0.61, 0.91; (PFS = 0.24 (95% CrI = 0.17, 0.31)) for TAS-102; 0.80 (95% CrI = 0.79, 0.90; PFS = 0.18 (95% CrI = 0.13, 0.24)) for fruquintinib; 0.83 (95% CrI = 0.50, 0.99; PFS = 0.42 (95% CrI = 0.20, 0.75)) for atezolizumab+cobimetinib; and 1.03 (95% CrI = 0.55, 1.65; PFS = 0.67 (95% CrI = 0.29, 1.01)) for atezolizumab.Conclusion: In this independent NMA of survival data, all later-line mCRC therapies but atezolizumab monotherapy exhibited superiority in 12-month PFS and OS over placebo. TAS+bevacizumab emerged as the most dominant option and may be the preferred choice, with fruquintinib, regorafenib, and TAS-102 monotherapy showing statistically significant but lower PFS and OS benefits.Registration: PROSPERO: CRD42022371953.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"923-932"},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141283444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What are the costs of managing neck and low back pain in Brazil? Investigation of a ten-year period from the perspective of the Brazilian public health system. 巴西管理颈部和腰背疼痛的成本是多少？从巴西公共卫生系统的角度对十年间的情况进行调查。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-10-01 Epub Date: 2024-06-05 DOI: 10.1080/14737167.2024.2364038

Yara Andrade Marques, Luciana Alves Custódio, Gisela Cristiane Miyamoto, Cristina Maria Nunes Cabral, Aline Martins de Toledo, Rodrigo Luiz Carregaro

{"title":"What are the costs of managing neck and low back pain in Brazil? Investigation of a ten-year period from the perspective of the Brazilian public health system.","authors":"Yara Andrade Marques, Luciana Alves Custódio, Gisela Cristiane Miyamoto, Cristina Maria Nunes Cabral, Aline Martins de Toledo, Rodrigo Luiz Carregaro","doi":"10.1080/14737167.2024.2364038","DOIUrl":"10.1080/14737167.2024.2364038","url":null,"abstract":"Introduction: Considering the prospects of increased prevalence and disability due to neck and low back pain, it is relevant to investigate the care processes adopted, to assist future public policies and decision-making for a better allocation of resources. Objective: the aim of this study was to estimate the costs arising from inpatient and outpatient care of individuals with Neck Pain (NP) and Low Back Pain (LBP) in Brazil, between 2010 and 2019.Methods: This is a cost-of-illness study from the perspective of the Brazilian public health system, based on health conditions with high prevalence (neck and low back pain). Data were presented descriptively using absolute and relative values.Results: Between 2010 and 2019, the health system spent more than $600 million (R$ 2.3 billion) to treat NP and LBP in adults, and LBP accounted for most of the expenses. Female had higher absolute expenses in inpatient care and in the outpatient system.Conclusion: Our study showed that the costs with NP and LBP in Brazil were considerable. Female patients had higher outpatient costs and male patients had higher hospitalization costs. Healthcare expenses were concentrated for individuals between 34 and 63 years of age.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"943-952"},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141237120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness analysis comparing single-pill combination of perindopril/amlodipine/indapamide to the free equivalent combination in patients with hypertension from an Italian national health system perspective. 从意大利国家卫生系统的角度，比较高血压患者服用培哚普利/氨氯地平/吲达帕胺单药组合与免费等效组合的成本效益分析。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-10-01 Epub Date: 2024-06-14 DOI: 10.1080/14737167.2024.2365988

Pierre Levy, Tobiasz Lemański, Catriona Crossan, Anna Lefebvre, Jean-Baptiste Brière, Luca Degli Esposti, Zeba M Khan

{"title":"Cost-effectiveness analysis comparing single-pill combination of perindopril/amlodipine/indapamide to the free equivalent combination in patients with hypertension from an Italian national health system perspective.","authors":"Pierre Levy, Tobiasz Lemański, Catriona Crossan, Anna Lefebvre, Jean-Baptiste Brière, Luca Degli Esposti, Zeba M Khan","doi":"10.1080/14737167.2024.2365988","DOIUrl":"10.1080/14737167.2024.2365988","url":null,"abstract":"Objective: To evaluate the cost-effectiveness of a single-pill combination (SPC) of perindopril/amlodipine/indapamide versus its free equivalent combination (FEC) in adults with hypertension in Italy.Methods: A Markov model was developed to perform a cost-utility analysis with a lifetime horizon and an Italian healthcare payer's perspective. In the model, the additional effect of the SPC on blood pressure level compared with the FEC was translated into a decreased risk of cardiovascular events and CKD, which was modeled via Framingham risk algorithms. Difference in persistence rates of SPC and FEC were modeled via discontinuation rates.Results: A perindopril/amlodipine/indapamide SPC is associated with lower cost and better health outcomes compared to its FEC. Over a lifetime horizon, it is associated with a 0.050 QALY gain and cost savings of €376, resulting from lower cardiovascular event rates. In the alternative scenario, where different approach for modeling impact of adherence was considered, incremental gain of 0.069 QALY and savings of €1,004 were observed. Results were robust to sensitivity and scenario analyses, indicating that use of this SPC is a cost-effective strategy.Conclusions: The findings indicate that a perindopril/amlodipine/indapamide SPC is a cost-saving treatment option for hypertension in Italy, compared to its FEC.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"967-975"},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141283445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial. 中国晚期鳞状非小细胞肺癌一线舍曲利单抗联合化疗的成本效益分析：基于ASTRUM-004试验。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-10-01 Epub Date: 2024-07-15 DOI: 10.1080/14737167.2024.2379600

Heng Xiang, Kehui Meng, Meiyu Wu, Chongqing Tan

{"title":"Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial.","authors":"Heng Xiang, Kehui Meng, Meiyu Wu, Chongqing Tan","doi":"10.1080/14737167.2024.2379600","DOIUrl":"10.1080/14737167.2024.2379600","url":null,"abstract":"Objective: In the ASTRUM-004 trial, serplulimab plus chemotherapy demonstrated significantly improved survival and controllable safety. This study assessed the cost-effectiveness of serplulimab plus chemotherapy in advanced squamous non-small cell lung cancer (sqNSCLC), considering the perspective of the Chinese healthcare system.Methods: A decision tree and a Markov model were constructed to simulate the treatment. The interesting results included total cost, life-years (LYs), quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs). Scenario, one-way and probabilistic sensitivity analyses were used to examine model instability.Results: Compared with placebo plus chemotherapy, serplulimab plus chemotherapy had an ICER of $55,539.46/QALY ($47,278.84/LY). The ICERs were estimated to be $58,706.03/QALY, $48,978.34/QALY and $59,709.54/QALY inpatients with programmed death-ligand 1 expression level of tumor proportion score (TPS) < 1%, 1% ≤ TPS < 50%, and TPS ≥ 50%. The cost-effective prices of serplulimab were $168.276/100 mg, $349.157/100 mg, and $530.039/100 mg at the willingness-to-pay threshold of $12,574.30/QALY, $25,148.60/QALY, and $37,722.90/QALY. Patient weight and price of serplulimab created the most significant impact. Presently, the probability of serplulimab plus chemotherapy being cost-effective was 14.15%.Conclusion: Compared with placebo plus chemotherapy, serplulimab plus chemotherapy might not be cost-effective in the first-line treatment for advanced sqNSCLC.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1043-1051"},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141563086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multiple sclerosis: economic burden, therapeutic advances, and future forecasts in the Middle East and North Africa region. 多发性硬化症：中东和北非地区的经济负担、治疗进展和未来预测。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-10-01 Epub Date: 2024-06-07 DOI: 10.1080/14737167.2024.2364832

Radwa Ahmed Batran, Mohab Kamel, Ayman Bahr, Joseph Waheb, Ahmed Khalil, Mohamed Elsokary

{"title":"Multiple sclerosis: economic burden, therapeutic advances, and future forecasts in the Middle East and North Africa region.","authors":"Radwa Ahmed Batran, Mohab Kamel, Ayman Bahr, Joseph Waheb, Ahmed Khalil, Mohamed Elsokary","doi":"10.1080/14737167.2024.2364832","DOIUrl":"10.1080/14737167.2024.2364832","url":null,"abstract":"Introduction: Multiple sclerosis (MS) is a persistent condition characterized by immune-mediated processes in the central nervous system, affecting around 2.8 million individuals globally. While historically less prevalent in the Middle East and North Africa (MENA) region, recent trends mirror the global rise in MS.Area covered: The impact of MS is substantial, particularly in the MENA region, with costs per patient surpassing nominal GDP per capita in certain countries. Disease-modifying therapies aim to alleviate MS effects, but challenges persist, especially in managing progressive MS as it shifts from inflammatory to neurodegenerative phases. Limited resources in the MENA region hinder care delivery, though awareness initiatives and multidisciplinary centers are emerging. Contrary to global projections of a decline in the MS market, the MENA region is poised for growth due to increased prevalence, healthcare expenditures, and infrastructure investments.Expert opinion: This review underscores the urgent necessity for effective treatments, robust disease management, and early diagnosis in tackling MS's repercussions in the MENA region. Bolstering resources tailored to MS patients and elevating the quality of care stand as pivotal strategies for enhancing health outcomes in this context. Taking decisive action holds the key to enhancing the overall well-being of individuals grappling with MS.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"873-882"},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141237112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A retrospective budget impact analysis of fidaxomicin treatment for Clostridioides difficile infections (CDI) in Germany. 德国治疗艰难梭菌感染 (CDI) 的菲达霉素预算影响回顾分析。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-10-01 Epub Date: 2024-05-09 DOI: 10.1080/14737167.2024.2352005

Ann-Cathrine Siefen, Melina Sophie Kurte, Anna Marie Bauer, Oliver A Cornely, Sebastian Wingen-Heimann, Florian Kron

{"title":"A retrospective budget impact analysis of fidaxomicin treatment for Clostridioides difficile infections (CDI) in Germany.","authors":"Ann-Cathrine Siefen, Melina Sophie Kurte, Anna Marie Bauer, Oliver A Cornely, Sebastian Wingen-Heimann, Florian Kron","doi":"10.1080/14737167.2024.2352005","DOIUrl":"10.1080/14737167.2024.2352005","url":null,"abstract":"Background: Clostridioides difficile is the most common cause of healthcare-associated diarrhea. Research suggests that treating C. difficile infections (CDI) with fidaxomicin (FDX) is more effective than vancomycin (VAN), with potential cost savings. The objective was to calculate the budget impact of FDX treatment compared to VAN from a German payer perspective.Research design and methods: The analysis used real-world data of patients discharged from University Hospital Cologne between Jan-01-2018 and Dec-31-2019. We identified recurrent and non-recurrent CDI cases and calculated direct treatment costs based on G-DRG flat rates. To calculate average costs per treatment and the budget impact, recurrence probabilities for VAN and FDX were taken from published evidence (28-day and 90-day scenarios).Results: Totally, 475 cases were analyzed, thereof 421 non-recurrent, causing mean costs of €32,901 per case (95% CI: 27.752-38.050). Thirty-two patients experienced a recurrence within 28 days, yielding mean costs of €10,952 (95% CI: 5.627-16.277) for their additional hospital stay. The resulting budget impact was €1,303 (95% CI: 670-1.937) in favor of FDX, ranging from €148.34 to €2,190.30 in scenario analyses.Conclusion: The analysis indicates FDX treatment can lead to cost savings compared to VAN. Future research should focus on specific patient groups, such as refractory CDI patients.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"933-942"},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140860463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mapping the World Health Organization Disability Assessment Scale 2.0 to the EQ-5D-5L in patients with mental disorders. 将世界卫生组织残疾评估量表 2.0 与精神障碍患者的 EQ-5D-5L 相匹配。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-10-01 Epub Date: 2024-07-11 DOI: 10.1080/14737167.2024.2376100

Edimansyah Abdin, Vanessa Seet, Anitha Jeyagurunathan, Sing Chik Tan, Muhammad Iskandar Shah Mohmad Khalid, Yee Ming Mok, Swapna Verma, Mythily Subramaniam

{"title":"Mapping the World Health Organization Disability Assessment Scale 2.0 to the EQ-5D-5L in patients with mental disorders.","authors":"Edimansyah Abdin, Vanessa Seet, Anitha Jeyagurunathan, Sing Chik Tan, Muhammad Iskandar Shah Mohmad Khalid, Yee Ming Mok, Swapna Verma, Mythily Subramaniam","doi":"10.1080/14737167.2024.2376100","DOIUrl":"10.1080/14737167.2024.2376100","url":null,"abstract":"Objective: The current study aims to develop an algorithm for mapping the WHODAS 2.0 to the EQ-5D-5 L for patients with mental disorders.Methods: This cross-sectional study was conducted at the Institute of Mental Health and Community Wellness Clinics in Singapore between June 2019 and November 2022. We included four regression methods including the Ordinary Least Square (OLS) regression, the Tobit regression model (Tobit), the robust regression with MM estimator (MM), and the adjusted limited dependent variable mixture model (ALDVMM) to map EQ-5D-5 L utility scores from the WHODAS 2.0.Results: A total of 797 participants were included. The mean EQ-5D-5 L utility and WHODAS 2.0 total scores were 0.615 (SD = 0.342) and 11.957 (SD = 8.969), respectively. We found that the EQ-5D-5 L utility score was best predicted by the robust regression model with the MM estimator. Our findings suggest that the WHODAS 2.0 total scores were significantly and inversely associated with the EQ-5D-5 L utility scores.Conclusion: This study provides a mapping algorithm for converting the WHODAS 2.0 scores into EQ-5D-5 L utility scores which can be implemented using a simple online calculator in the following web application: https://eastats.shinyapps.io/whodas_eq5d/.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1009-1015"},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness analysis. 中国HER2阴性晚期胃癌患者Pembrolizumab联合化疗与安慰剂联合化疗的成本效益分析。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-10-01 Epub Date: 2024-07-12 DOI: 10.1080/14737167.2024.2378986

Zhiwei Zheng, Xiaobing Song, Hongfu Cai, Huide Zhu

{"title":"Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness analysis.","authors":"Zhiwei Zheng, Xiaobing Song, Hongfu Cai, Huide Zhu","doi":"10.1080/14737167.2024.2378986","DOIUrl":"10.1080/14737167.2024.2378986","url":null,"abstract":"Objective: This study aims to conduct a cost-effectiveness analysis of pembrolizumab in combination with chemotherapy for HER2-negative advanced gastric cancer in China.Methods: A partitioned survival approach model was constructed to simulate the progression of HER2-negative advanced gastric cancer and evaluate the outcomes of different treatment strategies. We calculated incremental cost-effectiveness ratios (ICER) to assess the cost associated with each quality-adjusted life-year (QALY) gained. One-way sensitivity analysis and probabilistic sensitivity analysis were performed to assess robustness and reliability.Results: The analysis conducted in the base case demonstrated that the ICER associated with pembrolizumab was $177405.83/QALY gained in all population. In the subgroup analysis, it was found that individuals with a PD-L1 CPS ≥ 1 and those with a PD-L1 CPS ≥ 10 had ICERs of $152397.06/QALY and $109534.13/QALY, respectively. All ICER values for both the all population groups and the subgroups exceeded the WTP threshold in China. Our analysis shows the robustness of these results, as they remained consistent when input parameters were varied within a ± 25% range.Conclusion: The findings of this cost-effectiveness analysis suggest that pembrolizumab in combination with chemotherapy is not a cost-effective treatment option for HER2-negative advanced gastric cancer in China.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1017-1025"},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmaceutical innovativeness index: methodological approach for assessing the value of medicines - a case study of oncology drugs. 药品创新指数：评估药品价值的方法论--肿瘤药物案例研究。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-10-01 Epub Date: 2024-06-13 DOI: 10.1080/14737167.2024.2365985

Ludmila P Gargano, Juliana Alvares-Teodoro, Francisco de A Acurcio, Augusto A Guerra

{"title":"Pharmaceutical innovativeness index: methodological approach for assessing the value of medicines - a case study of oncology drugs.","authors":"Ludmila P Gargano, Juliana Alvares-Teodoro, Francisco de A Acurcio, Augusto A Guerra","doi":"10.1080/14737167.2024.2365985","DOIUrl":"10.1080/14737167.2024.2365985","url":null,"abstract":"Background: We propose a framework to assess the value of pharmaceutical innovations, with explicit clinical and methodological parameters, based on the therapeutic value and health needs.Research design and methods: The study was based on the adaptation of health technology assessment methods documented in the literature, which was applied to a sample of oncological drugs. Difficulties and issues during the application of those tools were identified and addressed to develop a new framework with new and revised domains and clear classification criterion for each domain. Scores were assigned to each level and domain according to their relevance to generate the final score of innovativeness.Results: The Pharmaceutical Innovation Index (PII) includes four domains, two related to clinical and social dimensions - Therapeutic Need and Added Therapeutic Value - and other two about methodological features - Study Design and Quality (risk of bias). The scores combined after assigned to each domain results Index of the Innovativeness of the medicines represents the degree of pharmaceutical innovation.Conclusion: This work proposes a transparent methodology with well-defined criteria and script; the algorithm developed with authors' weightings and criteria may be switched to best adjust to other applications, perspective or clinical indications, while keeping the transparency and objectiveness.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"977-986"},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141300478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preferences of people with diabetes for diabetes care in Germany: a discrete choice experiment. 德国糖尿病患者对糖尿病护理的偏好：离散选择实验。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-10-01 Epub Date: 2024-06-21 DOI: 10.1080/14737167.2024.2369293

Markus Vomhof, Anna C Boersma, Dorijn F L Hertroijs, Matthias Kaltheuner, Michael Krichbaum, Bernhard Kulzer, Andrea Icks, Mickael Hiligsmann

{"title":"Preferences of people with diabetes for diabetes care in Germany: a discrete choice experiment.","authors":"Markus Vomhof, Anna C Boersma, Dorijn F L Hertroijs, Matthias Kaltheuner, Michael Krichbaum, Bernhard Kulzer, Andrea Icks, Mickael Hiligsmann","doi":"10.1080/14737167.2024.2369293","DOIUrl":"10.1080/14737167.2024.2369293","url":null,"abstract":"Objectives: The objective of this study is to elicit health care preferences of people with diabetes and identify classes of people with different preferences.Methods: A discrete choice experiment was conducted among people with diabetes in Germany comprising attributes of role division in daily diabetes care planning, type of lifestyle education, support for correct medication intake, consultation frequency, emotional support, and time spent on self-management. A conditional logit model and a latent class model were used to elicit preferences toward diabetes care and analyze preference heterogeneity.Results: A total of 76 people with diabetes, recruited in two specialized diabetes care centers in Germany (mean age 51.9 years, 37.3% women, 49.1% type 2 diabetes mellitus, 50.9% type 1 diabetes mellitus), completed the discrete choice experiment. The most important attributes were consultation frequency, division in daily diabetes care planning, and correct medication intake. The latent class model detected preference heterogeneity by identifying two latent classes which differ mainly with respect to lifestyle education and medication intake.Conclusion: While the majority of people with diabetes showed preferences in line with current health care provision in Germany, a relevant subgroup wished to strengthen lifestyle education and medication intake support with an aid or website.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"997-1007"},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141316928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0